CN113329746B - 用于治疗或预防疼痛、炎症和/或自身免疫的化合物 - Google Patents

用于治疗或预防疼痛、炎症和/或自身免疫的化合物 Download PDF

Info

Publication number
CN113329746B
CN113329746B CN202080010393.8A CN202080010393A CN113329746B CN 113329746 B CN113329746 B CN 113329746B CN 202080010393 A CN202080010393 A CN 202080010393A CN 113329746 B CN113329746 B CN 113329746B
Authority
CN
China
Prior art keywords
polymorph
pain
polymorphs
inflammation
autoimmunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080010393.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113329746A (zh
Inventor
E·卡普兰
R·赫特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novaremed Ltd
Original Assignee
Novaremed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaremed Ltd filed Critical Novaremed Ltd
Publication of CN113329746A publication Critical patent/CN113329746A/zh
Application granted granted Critical
Publication of CN113329746B publication Critical patent/CN113329746B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080010393.8A 2019-01-23 2020-01-22 用于治疗或预防疼痛、炎症和/或自身免疫的化合物 Active CN113329746B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19153315 2019-01-23
EP19153315.7 2019-01-23
PCT/EP2020/051528 WO2020152226A1 (en) 2019-01-23 2020-01-22 Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity

Publications (2)

Publication Number Publication Date
CN113329746A CN113329746A (zh) 2021-08-31
CN113329746B true CN113329746B (zh) 2025-05-02

Family

ID=65228356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080010393.8A Active CN113329746B (zh) 2019-01-23 2020-01-22 用于治疗或预防疼痛、炎症和/或自身免疫的化合物

Country Status (17)

Country Link
US (1) US11891350B2 (https=)
EP (1) EP3860582B1 (https=)
JP (2) JP7611148B2 (https=)
KR (1) KR20210119403A (https=)
CN (1) CN113329746B (https=)
AU (1) AU2020210831B2 (https=)
BR (1) BR112021019476A2 (https=)
CA (1) CA3118996A1 (https=)
DK (1) DK3860582T3 (https=)
ES (1) ES2913977T3 (https=)
IL (1) IL282718B2 (https=)
PL (1) PL3860582T3 (https=)
PT (1) PT3860582T (https=)
RS (1) RS63270B1 (https=)
SG (1) SG11202111773QA (https=)
WO (1) WO2020152226A1 (https=)
ZA (1) ZA202107346B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3939578A1 (en) * 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
WO2026037478A1 (en) 2023-08-11 2026-02-19 Novaremed AG (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102821761A (zh) * 2009-09-09 2012-12-12 诺瓦麦有限公司 用于治疗疼痛和炎症的n-取代的苯丙酰胺或苯丙烯酰胺
CN103998420A (zh) * 2011-12-08 2014-08-20 诺瓦麦有限公司 (s)2-n(3-o-(丙2-醇)-1-丙基-4-羟基苯)-3-苯基丙酰胺的分离的立体异构形式

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642290B2 (en) 2002-10-03 2010-01-05 Novaremed Limited Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
JP4939396B2 (ja) * 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Aids及び他のウイルス性疾患及びhiv関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
US8802734B2 (en) 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
GB0916073D0 (en) 2009-09-14 2009-10-28 Cintec Int Ltd Improvements in and relating to building anchor systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102821761A (zh) * 2009-09-09 2012-12-12 诺瓦麦有限公司 用于治疗疼痛和炎症的n-取代的苯丙酰胺或苯丙烯酰胺
CN103998420A (zh) * 2011-12-08 2014-08-20 诺瓦麦有限公司 (s)2-n(3-o-(丙2-醇)-1-丙基-4-羟基苯)-3-苯基丙酰胺的分离的立体异构形式

Also Published As

Publication number Publication date
AU2020210831B2 (en) 2025-02-13
ZA202107346B (en) 2023-10-25
JP7611148B2 (ja) 2025-01-09
PL3860582T3 (pl) 2022-08-01
ES2913977T3 (es) 2022-06-07
DK3860582T3 (da) 2022-05-23
IL282718B1 (en) 2024-04-01
KR20210119403A (ko) 2021-10-05
EP3860582A1 (en) 2021-08-11
US11891350B2 (en) 2024-02-06
IL282718B2 (en) 2024-08-01
CA3118996A1 (en) 2020-07-30
SG11202111773QA (en) 2021-11-29
AU2020210831A1 (en) 2021-05-20
JP2025036479A (ja) 2025-03-14
CN113329746A (zh) 2021-08-31
RS63270B1 (sr) 2022-06-30
JP2022518288A (ja) 2022-03-14
IL282718A (en) 2021-06-30
WO2020152226A1 (en) 2020-07-30
PT3860582T (pt) 2022-07-08
BR112021019476A2 (pt) 2021-11-30
EP3860582B1 (en) 2022-05-04
US20220002228A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
JP5371790B2 (ja) 睡眠および認知に関するうつ病における残存症状の治療のための組み合わされたセロトニン再取り込み、5−ht3および5−ht1a活性を有する化合物としての1−[2−(2,4−ジメチルフェニルスルファニル)フェニル]ピペラジン
KR101536023B1 (ko) 조합된 sert, 5-ht3 및 5-ht1a 활성을 가진 화합물의 치료 용도
JP2025036479A (ja) 疼痛、炎症および/または自己免疫の処置または予防における使用のための化合物
JP2020079263A (ja) 結晶形およびその使用
CN102325778A (zh) 盐酸纳美芬二水合物
JP5860895B2 (ja) 5−メチル−1−(ナフタレン−2−イル)−1h−ピラゾール誘導体
TWI441630B (zh) 曲馬朵(Tramadol)和可舒葆(Coxib)之共結晶物
TW202106680A (zh) Glyt1抑制劑之固體形式
JP6185490B2 (ja) 3−(4−ニトロ−1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオンの固体形態
JP5544535B2 (ja) 1r,2s−メトキサミンを用いた便失禁および他の状態の処置
EP2475361B1 (en) N-substituted benzenepropanamides for use in the treatment of pain and inflammation
JP6610793B2 (ja) 環状アミン誘導体の結晶及びその医薬用途
JPH04178356A (ja) 光学活性なベンジルアルコール誘導体及びその用途
HK40061961A (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
HK40061961B (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
WO2026037478A1 (en) (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain
WO2014164784A1 (en) Hdac inhibitor polymorphic forms and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant